FIELD: chemical-pharmaceutical industry.
SUBSTANCE: invention relates to a novel chromon oxime derivative of formula (I), also relates to pharmaceutical compositions containing said compound, and to their use in the treatment or prevention of conditions associated with altered glutamatergic signaling and/or function, or conditions that can be influenced, changing the level of glutamate or signal transmission, in particular Parkinson's disease.
.
EFFECT: technical result: new compound of formula (I) is obtained which is a modulator of brain permeability mGluRs of the nervous system and, in addition, provides an advantageous high permeability of the brain after oral administration.
14 cl, 10 dwg, 3 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ORGANIC COMPOUNDS | 2015 |
|
RU2709786C2 |
| THERAPEUTIC FOR THE TREATMENT OF LEWY BODY DISEASE CONTAINING PYRAZOLOQUINOLINE DERIVATIVE | 2018 |
|
RU2802212C2 |
| 3-AZABICYCLO[3,1,0]HEXYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | 2009 |
|
RU2510396C2 |
| ETHINYL DERIVATIVES | 2017 |
|
RU2745068C2 |
| ETHYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR | 2016 |
|
RU2721776C2 |
| COMPOSITIONS AND METHODS ASSOCIATED THEREWITH | 2017 |
|
RU2764716C2 |
| 1,2,4-TRIAZOLO[4,3-A]PYRIDINE COMPOUNDS AND USE THEREOF AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | 2015 |
|
RU2695651C2 |
| SUCCINATE 2-((4-(1-METHYL-4-(PYRIDIN-4-YL)-1H-PYRAZOL-3-YL)PHENOXY)METHYL)QUINOLINE SALT | 2007 |
|
RU2430918C2 |
| NOVEL APPLICATION OF LIGNAN COMPOUNDS | 2006 |
|
RU2354370C1 |
| GSK-3 INHIBITORS | 2006 |
|
RU2449998C2 |
